If the detail in the report to be released today is as forecast, it will be good for relenza; but the risk is that we will incur collateral damage. The only part the general population will pick up on will be influenza antiviral side effects; not the part which distinguishes relenza from tamiflu.
Our saving grace is that our market is really the strategic stockpiling, which should be rebalanced in our favour over the course of this year. This is dependent on experts advising government, and they should be saying get as much relenza as you can into the stockpile.
I hope like you that we do get a boost, but I think it will continue to be a matter of WAITING, WAITING, WAITING.
BTA Price at posting:
84.0¢ Sentiment: Buy Disclosure: Held
